SCIENTIFIC PUBLICATIONS
Publications
Improving antibiotic prescribing – Recommendations for funding and pricing policies to enhance use of point-of-care tests. Health Policy OPEN. Read here.
Point-of-care tests to manage acute respiratory tract infections in primary care: a systematic review and qualitative synthesis of healthcare professional and patient views. Journal of Antimicrobial Chemotherapy. Read here.
Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices. Diagnostics (Basel). Read here.
Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections–Overview of Policies Applied in 17 European Countries, Antibiotics. Read here.
Stakeholders’ views and experiences on implementing new diagnostics in primary care to support management of community-acquired acute respiratory tract infections: a qualitative study, Frontiers Public Health. Read here.
Usability of OMOP Common Data Model for Detailed Lab Microbiology Results, IOS Press. Read here.
Does diagnostic testing always decrease antibiotics prescriptions?, The European Journal of Health Economics. Read here.
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance, PharmacoEconomics. Read here.
Point of care testing, antibiotic prescribing and prescribing confidence for respiratory tract infections in primary care: Prospective audit in 18 European countries, BJGP Open. Read here.
Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis, Clinical Microbiology and Infection. Read here.
Health‑Economic Analyses of Diagnostics: Guidance on Design and Reporting, Pharmaco Economics. Read here.
Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model, Health Economics Review. Read here.
Primary care for patients with respiratory tract infection before and early on in the COVID-19 pandemic: an observational study in 16 European countries, BMJ Open. Read here.
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review, Springer Nature. Read here.
Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis, Clinical Microbiology and Infection. Read here.
Multi-Criteria Decision Analysis to prioritise hospital admission of patients affected by COVID-19 in settings with hospital-bed shortage, ScienceDirect. Read here
Overview of AMR-related resources and services, public report. Read here
Posters
Barriers and Facilitators for the Use of Point of Care Diagnostics in Patients With Respiratory Tract Infections in Outpatient Care Related to the Peri-Launch Phase, presented at ISPOR Europe 2023. Read here.
Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections, presented at ISPOR Europe 2023. Read here.
Analysing Microbiology In Vitro Diagnostics data using the OMOP DCM and SNOMED CT Encoding, presented at SNOMED Expo 2020. Read here
Health-Economics Modelling of Infectious Disease Diagnostics: current approaches and future opportunities, presented at ISPOR Europe 2019 in Copenhagen. Read here
Reports
Deliverable 5.4: Recommendations for innovative fit for purpose pricing and funding models for CA-ARTI diagnostics. Read here
VALUE-Dx Task 3.4 Modelling report. Read here
HTA, Reimbursement and Pricing of Diagnostic Tests for CA-ARTI – An international overview of policies (Task 5.5). Read here
Interoperable Networks for AMR Laboratory Data – An overarching review of Task 3.4 and federated networking. Read here
OHDSI-OMOP – A proposed standard for AMR data Modelling: Readiness and Recommendations (Task 3.4). Read here
POC 1 Infrastructure documentation (Task 3.4). Read here
EAP executive summary
(full versions available on the login area of the website)
EAP Session 1 – Executive Summary. Read here
EAP Session 2 – Executive Summary. Read here
EAP Session 3 – Executive Summary. Read here
EAP Session 4 – Executive Summary. Read here
EAP Session 5 – Executive Summary. Read here
EAP Session 6 – Executive Summary. Read here
EAP Session 7 – Executive Summary. Read here
EAP Session 8 – Executive Summary. Read here
Social Media
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.